CIBC Asset Management Inc Purchases 19,154 Shares of Cencora, Inc. $COR

CIBC Asset Management Inc boosted its position in Cencora, Inc. (NYSE:COR) by 28.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 85,355 shares of the company’s stock after purchasing an additional 19,154 shares during the quarter. CIBC Asset Management Inc’s holdings in Cencora were worth $28,816,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Cencora by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after purchasing an additional 221,570 shares during the period. State Street Corp boosted its stake in Cencora by 9.3% in the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after purchasing an additional 782,911 shares during the period. Geode Capital Management LLC boosted its stake in Cencora by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after purchasing an additional 169,055 shares during the period. JPMorgan Chase & Co. boosted its stake in Cencora by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock valued at $1,461,965,000 after purchasing an additional 821,098 shares during the period. Finally, Boston Partners boosted its stake in Cencora by 2.0% in the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after purchasing an additional 89,506 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

Shares of NYSE COR opened at $264.40 on Thursday. The stock has a market capitalization of $51.44 billion, a PE ratio of 20.28, a P/E/G ratio of 1.22 and a beta of 0.59. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The business has a fifty day moving average price of $294.84 and a two-hundred day moving average price of $331.59. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has approved a share repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s payout ratio is 18.40%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Weiss Ratings downgraded Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Citigroup reduced their price target on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Robert W. Baird dropped their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Wells Fargo & Company dropped their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Twelve analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.